Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SELLAS Life Sciences (SLS) Accumulated Expenses (2019 - 2024)

SELLAS Life Sciences (SLS) has disclosed Accumulated Expenses for 9 consecutive years, with $5.2 million as the latest value for Q2 2024.

  • On a quarterly basis, Accumulated Expenses changed N/A to $5.2 million in Q2 2024 year-over-year; TTM through Jun 2024 was $5.2 million, a N/A change, with the full-year FY2023 number at $7.6 million, up 21.7% from a year prior.
  • Accumulated Expenses was $5.2 million for Q2 2024 at SELLAS Life Sciences, down from $7.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $7.6 million in Q4 2023 to a low of $1.9 million in Q4 2020.
  • A 5-year average of $4.7 million and a median of $4.9 million in 2022 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 138.11% in 2022, then grew 21.7% in 2023.
  • SELLAS Life Sciences' Accumulated Expenses stood at $1.9 million in 2020, then skyrocketed by 38.0% to $2.6 million in 2021, then soared by 138.11% to $6.3 million in 2022, then increased by 21.7% to $7.6 million in 2023, then tumbled by 32.25% to $5.2 million in 2024.
  • Per Business Quant, the three most recent readings for SLS's Accumulated Expenses are $5.2 million (Q2 2024), $7.6 million (Q4 2023), and $6.3 million (Q4 2022).